Syndax Pharmaceuticals Inc (SNDX)
Syndax Pharmaceuticals Inc (SNDX) from its SEC filings: 2025 revenue $172.4 million (+628% vs the year before), net margin -166%, free cash flow -$323.2 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $172.4 million |
| Revenue growth | +628% |
| Net income | -$285.4 million |
| Net margin | -165.6% |
| Free cash flow | -$323.2 million |
| Diluted EPS | $-3.29 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +92% |
| Cash | $336.5 million |
| Share count, 1 year | +4% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.